Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

doi:10.1038/s41467-025-63960-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications - 6 Oct 2025

Lei Ming, Overman Michael J, Yao Jin, André Thierry, Lonardi Sara, Lenz Heinz-Josef, Aglietta Massimo, Gelsomino Fabio, McDermott Ray, Wong Ka Yeung Mark, Morse Michael A, Van Cutsem Eric, Hendlisz Alain, Cardin Dana B, Neyns Bart, Hill Andrew, Krishnamurthy Anuradha, Chen Franklin, Kochuparambil Samith, Jenq Robert R, Abdullaev Sandzhar, He Beilei, Novosiadly Ruslan, Kopetz Scott

Abstract excerpt

Nivolumab alone and in combination with ipilimumab demonstrated durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer in the phase 2 CheckMate 142 study. Here, we report exploratory biomarker analyses from CheckMate 142 evaluating associations between various tissue biomarkers and the efficacy of nivolumab monotherapy...

Read the complete abstract on PubMed

Topics

Humans
Ipilimumab
Nivolumab
Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Microsatellite Instability

Antineoplastic Combined Chemotherapy Protocols

Inflammation

Mutation

Biomarkers, Tumor

Male

Female

Treatment Outcome

Antineoplastic Agents, Immunological

Source

Open in PubMed Open full text

Identifiers

PMID: 41053075
DOI: 10.1038/s41467-025-63960-8
PMCID: PMC12501054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.PMID 41053075Read ↗

Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesSemantic proximity Read ↗

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Tumor Immune Cell Infiltration Patterns and Predictable Clinical Benefit with Nivolumab in Combination with Ipilimumab for 3P ImplementationSemantic proximity Read ↗

Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.Semantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activitySemantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.Semantic proximity Read ↗

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.Semantic proximity Read ↗

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.